References
- Greiner J, Ringhoffer M, Taniguchi M et al. Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic tumor-associated antigen overexpressed in acute and chronic myeloid leukemia. Exp. Hematol.30, 1029–1025 (2002).
- Greiner J, Ringhoffer M, Taniguchi M et al. Characterization of several leukemia associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia (AML/CML). Int. J. Cancer106, 224–231 (2003).
- Greiner J, Döhner H, Schmitt M. Cancer vaccines for patients with acute myeloid leukemia (AML) – definition of targets and current clinical protocols (review). Haematologica91, 1653–1661 (2006).
- Greiner J, Guinn B, Döhner H et al. Leukemia-associated antigens (LAAs) are critical for the proliferation of acute myeloid leukemia cells. Clin. Cancer Res.14, 1–6 (2008).
- Ochi T, Fujiwara H, Suemori K et al. Aurora-A kinase: a novel target of cellular immunotherapy for leukemia. Blood113, 66–74 (2009).
- Sokal JE, Aungst CW, Snyderman M, Gomez G. Immunotherapy of chronic myelocytic leukemia: effects of different vaccination schedules. Ann. NY Acad. Sci.277, 367–383 (1976).
- Alsabti EA, Taleb AM, Raji HM et al. Clinical trials in vaccination with leukemia associated antigens in acute myelogenous leukemia. Jpn J. Exp. Med.49, 157–168 (1979).
- Alexander P, Powles R. Immunotherapy of human acute leukaemia. Clin. Haematol.2, 275–294 (1978).
- Cignetti A, Vallario A, Roato I et al. Leukemia-derived immature dendritic cells differentiate into functionally competent mature dendritic cells that efficiently stimulate T cell responses. J. Immunol.173, 2855–2865 (2004).
- Li L, Reinhardt P, Schmitt A et al. Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens. Cancer Immunol. Immunother.54, 685–693 (2005).
- Schmitt M, Schmitt A, Rojewski M et al. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma elicits immunological and clinical responses. Blood111, 1357–1365 (2008).
- Kuball J, de Boer K, Wagner E et al. Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with Montanide ISA51 and CpG7909. Cancer Immunol. Immunother.60, 161–171 (2011).
- Speiser DE, Liénard D, Rufer N et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest.115, 739–746 (2005).
- Adams S, O’Neill DW, Nonaka D et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J. Immunol.181, 776–784 (2008).
- Greiner J, Schmitt A, Giannopoulos K et al. High-dose RHAMM-R3 peptide peptide vaccination for patients with vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Haematologica95, 1191–1197 (2010).
- Oka Y, Tsuboi A, Taguchi T et al. Induction of WT-1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT-1 peptide vaccine and the resultant cancer regression. Proc. Natl Acad. Sci. USA101, 13885–13890 (2004).
- Maslak PG, Dao T, Krug LM et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood116, 171–179 (2010).
- Bocchia M, Gentili S, Abruzzese E et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet365, 657–662 (2005).
- Keilholz U, Letsch A, Busse A et al. A clinical and immunologic Phase 2 trial of Wilms tumor gene product 1 (WT-1) peptide vaccination in patients with AML and MDS. Blood113, 6541–6548 (2009).
- Barrett J, Rezvani K. Immunotherapy: can we include vaccines with stem-cell transplantation? Nat. Rev. Clin. Oncol.6, 503–505 (2009).
- Greiner J, Li L, Ringhoffer M et al. Identification and characterization of epitopes of the receptor for hyaluronic acid mediated motility (RHAMM/CD168) recognized by CD8 positive T cells of HLA-A2 positive patients with acute myeloid leukemia. Blood106, 938–945 (2005).
- Turley EA. Purification of a hyaluronate-binding protein fraction that modifies cell social behavior. Biochem. Biophys. Res. Commun.108, 1016–1024 (1982).
- Turley EA, Noble PW, Bourguignon LY. Signaling properties of hyaluronan receptors. J. Biol. Chem.277, 4589–4592 (2002).
- Hall CL, Yang B, Yang X et al. Overexpression of the hyaluronan receptor RHAMM is transforming and is also required for H-ras transformation. Cell82, 19–26 (1995).
- Hall CL, Lange LA, Prober DA et al. pp60 (c-src) is required for cell locomotion regulated by the hyaluronan receptor RHAMM. Oncogene13, 2213–2224 (1996).
- Buganim Y, Rotter V. RHAMM in the complex p53 cell cycle network. Cell Cycle7, 3287–3291 (2008).
- Slevin M, Krupinski J, Gaffney J et al. Hyaluronan-mediated angiogenesis in vascular disease: uncovering RHAMM and CD44 receptor signaling pathways. Matrix Biol.26, 58–68 (2007).
- Sohr S, Engeland K. RHAMM is differentially expressed in the cell cycle and downregulated by the tumor suppressor p53. Cell Cycle7, 3448–3460 (2008).
- Evanko SP, Tammi MI, Tammi RH, Wight TN. Hyaluronan dependent pericellular matrix. Adv. Drug Deliv. Rev.59, 1351–1365 (2007).
- Samuel SK, Hurta RA, Spearman MA et al. TGF-β 1 stimulation of cell locomotion utilizes the hyaluronan receptor RHAMM and hyaluronan. J. Cell Biol.123, 749–758 (1993).
- Assmann V, Marshall JF, Fieber C et al. The human hyaluronan receptor RHAMM is expressed as an intracellular protein in breast cancer cells. J. Cell Sci.111, 1685–1694 (1998).
- Abetamann V, Kern HF, Elsässer HP. Differential expression of the hyaluronan receptors CD44 and RHAMM in human pancreatic cancer cells. Clin. Cancer Res.2, 1607–1618 (1996).
- Li H, Guo L, Li JW et al. Expression of hyaluronan receptors CD44 and RHAMM in stomach cancers: relevance with tumour progression. Int. J. Oncol.17, 927–932 (2000).
- Rein DT, Roehrig K, Schöndorf T et al. Expression of the hyaluronan receptor RHAMM in endometrial carcinomas suggests a role in tumour progression and metastasis. J. Cancer Res. Clin. Oncol.129, 161–164 (2003).
- Teder P, Bergh J, Heldin P. Functional hyaluronan receptors are expressed on a squamous cell lung carcinoma cell line but not on other lung carcinoma cell lines. Cancer Res.55, 3908–3914 (1995).
- Ahrens T, Assmann V, Fieber C et al. CD44 is the principal mediator of hyaluronic-acid-induced melanoma cell proliferation. J. Invest. Dermatol.11, 93–101 (2000).
- Crainie M, Belch AR, Mant MJ. et al. Overexpression of the receptor for hyaluronan-mediated motility (RHAMM) characterizes the malignant clone in multiple myeloma: identification of three distinct RHAMM variants. Blood93, 1684–1696 (1999).
- Giannopoulos K, Dmoszynska A, Kowal M et al. Peptide vaccination elicits leukemia-associated antigen-specific cytototxic CD8+ T cell-responses in patients with chronic lymphocytic leukemia. Leukemia24, 798–805 (2010).
- Haber DA, Buckler AJ, Glaser T et al. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms’ tumor. Cell61, 1257–1269 (1990).
- Schmid D, Heinze G, Linnerth B et al. Prognostic significance of WT-1 gene expression at diagnosis in adult de novo acute myeloid leukemia. Leukemia11, 639–643 (1997).
- Cilloni D, Messa F, Arruga F et al. Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT-1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica93, 921–924 (2008).
- Greiner J, Ringhoffer M, Taniguchi M et al. mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. Int. J. Cancer108, 704–711 (2004).
- Cilloni D, Saglio G. WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome. Acta Haematol.112, 79–84 (2004).
- Burwell EA, McCarty GP, Simpson LA et al. Isoforms of Wilms’ tumor suppressor gene (WT1) have distinct effects on mammary epithelial cells. Effects of WT1 isoforms on breast epithelial cells. Oncogene26, 3423–3430 (2007).
- Inoue K, Tamaki H, Ogawa H et al. Wilms’ tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood91, 2969–2976 (1998).
- Algar EM, Khromykh T, Smith SI et al. A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukemia cell lines. Oncogene12, 1005–1014 (1996).
- Oka Y, Udaka K, Tsuboi A et al. Cancer immunotherapy targeting Wilms’ tumor gene WT1 product. J. Immunol.164, 1873–1880 (2000).
- Xue SA, Gao L, Thomas S et al. Development of a Wilms’ tumor antigen-specific T-cell receptor for clinical trials: engineered patient’s T cells can eliminate autologous leukemia blasts in NOD/SCID mice. Haematologica95, 126–134 (2010).
- Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT-1 peptide. Blood95, 286–293 (2000).
- Bellantuono I, Gao L, Parry S et al. Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood100, 3835–3837 (2002).
- Elisseeva OA, Oka Y, Tsuboi A et al. Humoral immune responses against Wilms tumor gene WT-1 product in patients with hematopoietic malignancies. Blood99, 3272–3279 (2002).
- Oka Y, Elisseeva OA, Tsuboi A et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms’ tumor gene (WT1) product. Immunogenetics.51, 99–107 (2000).
- Weber G, Karbach J, Kuçi S et al. WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation. Leukemia23, 1634–1642 (2009).
- Mailänder V, Scheibenbogen C, Thiel E et al. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT-1 peptide in the absence of hematological or renal toxicity. Leukemia18, 165–166 (2004).
- Rezvani K, Yong AS, Mielke S et al. Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies. Haematologica96, 432–440 (2011).
- Narita M, Masuko M, Kurasaki T et al. WT1 peptide vaccination in combination with imatinib therapy for a patient with CML in the chronic phase. Int. J. Med. Sci.7, 72–81 (2010).
- Oji Y, Oka Y, Nishida S et al. WT1 peptide vaccine induces reduction in minimal residual disease in an imatinib-treated CML patient. Eur. J. Haematol.85, 358–360 (2010).
- Oka Y, Tsuboi A, Murakami M et al. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int. J. Hematol.78, 56–61 (2003).
- Dengler R, Munstermann U, Al-Batran S et al. Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells. Br. J. Haematol.89, 250–257 (1995).
- Fujiwara H, El Ouriaghli F, Grube M et al. Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastase. Blood103, 3076–3083 (2004).
- Bories D, Raynal MC, Solomon DH et al. Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells. Cell59, 959–968 (1989).
- Yong AS, Szydlo RM, Goldman JM et al. Molecular profiling of CD34+ cells in CML patients identifies low expression of CD7 with high expression of proteinase 3 or elastase as predictors of longer survival. Blood107, 205–212 (2006).
- Molldrem J, Dermime S, Parker K et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood88, 2450–2457 (1996).
- Molldrem JJ, Lee PP, Wang C et al. A PR-1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia. Cancer Res.59, 2675–2681 (1999).
- Molldrem JJ, Lee PP, Kant S et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J. Clin. Invest.111, 639–647 (2003).
- Heslop HE, Stevenson FK, Molldrem JJ. Immunotherapy of hematologic malignancy. Hematology Am. Soc. Hematol. Educ. Program331–349 (2003).
- Qazilbash MH, Wieder E, Rios R et al. Vaccination with the PR-1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia. Blood104, 259 (2004) (Abstract).
- Qazilbash MH, Wieder E, Thall PF et al. PR-1 vaccine elicited immunological response after hematopoietic stem cell transplantation is associated with better clinical response event-free survival. Blood110, 577 (2007) (Abstract).
- Rezvani K. PR-1 vaccination in myeloid malignancies. Expert Rev. Vaccines7(7), 867–875 (2008).
- de Klein A, van Kesel AG, Grosvels G et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. Nature300, 765–767 (1982).
- Shtivelman E, Lifshitz B, Gale RP, Canani E. Fused transcript of abl and bcr genes in chronic myelogenus leukemia. Nature315, 550–554 (1985).
- Bocchia M, Wentworth PA, Southwood S et al. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood85(10), 2680–2684 (1995).
- Clark RE, Dodi IA, Hill SC et al. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the bcr-abl b3a2 fusion protein. Blood98, 2887–2893 (2001).
- Norbury LC, Clark RE, Christmas SE. b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia. Br. J. Haematol.109, 616–621 (2000).
- Pawelec G, Max H, Halder T et al. BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. Blood88, 2118–2124 (1996).
- Pinilla-Ibarz J, Cathcart K, Korontsvit T et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood95, 1781–1787 (2000).
- Cathcart K, Pinilla-Ibarz J, Korontsvit T et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood103, 1037–1042 (2004).
- Bocchia M, Defina M, Aprile L et al. Complete molecular response in CML after p210 Bcr-abl1-derived peptide vaccination. Nat. Rev. Clin. Oncol.7, 600–603 (2010).
- Rojas JM, Knight K, Wang L, Clark RE. Clinical evaluation of Bcr-abl peptide immunisation in chronic myeloidleukaemia: results of the EPIC study. Leukemia21, 2287–2295 (2007).
- Maslak PG, Dao T, Gomez M et al. A pilot vaccination trial of synthetic analog peptides derived from the BCRABL breakpoints in CML patients with minimal disease. Leukemia22, 1613–1616 (2008).
- Jain N, Reuben JM, Kantarjian H et al. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a Phase 2 trial. Cancer115, 3924–3934 (2009).
- Rezvani K, Yong AS, Mielke S et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood111, 236–242 (2007).
- Greiner J, Schmitt M, Li L et al. Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. Blood108, 4109–4117 (2006).